Catalio Capital Management, LP

John Henry Iucker is a Founding Partner and Head of Credit at Catalio Capital Management, where he focuses on providing senior-secured structured credit to healthcare and biomedical technology companies. He serves on the firm's Structured Opportunities Investment Committee and Management Committee. Before Catalio, he was a Principal and Fixed Income Portfolio Manager at Brown Advisory and held a seat on that firm's private income strategy investment committee. He holds a B.A. in Financial Economics from Johns Hopkins University and is a CFA charterholder.

Diamantis Xylas is a Founding Partner and Head of Research at Catalio Capital Management, where he leads the research team and invests in private biomedical technology companies. He sits on the investment committee of Catalio's Nexus strategy and the firmwide management committee. Before Catalio, he completed General Surgery residency training at Johns Hopkins Hospital and postgraduate medical and surgical training in London, and served as a visiting research fellow studying bladder cancer genetics at Weill Cornell Medical Center. He holds an MBBS from Imperial College School of Medicine and a BSc in Healthcare Management from Imperial College Business School.

Isaac Ro is a Partner at Catalio Capital Management. He was previously Executive Chairman of Haystack Oncology (sold to Quest Diagnostics), CFO of Sema4, which he took public in 2021, and CFO of Thrive Earlier Detection (sold to Exact Sciences). Earlier he led U.S. Medical Technology and Life Science Tools equity research teams at Goldman Sachs and held a similar role at Leerink Partners, and he holds a B.A. in History from Middlebury College.

Jacob Vogelstein co-founded Catalio Capital Management and serves as Managing Partner, focusing on investments in private healthcare companies and sitting on the firm's Nexus strategy Investment Committee and Management Committee. He was previously a General Partner at Camden Partners Holdings, where he invested in biomedical technology, and earlier held faculty positions at Johns Hopkins University's Applied Physics Laboratory and Whiting School of Engineering. He holds a BSc in Bio-Electrical Engineering from Brown University and a PhD in Biomedical Engineering from the Johns Hopkins University School of Medicine.

Adam Riess is the Bloomberg Professor of Physics at Johns Hopkins University, with expertise spanning physics and big data. He holds a BS from the Massachusetts Institute of Technology and a PhD from Harvard University. His honors include the 2011 Nobel Prize in Physics, the 2015 Breakthrough Prize in Fundamental Physics, and a 2008 MacArthur Fellowship, and he was elected to the National Academy of Sciences in 2009.

Alan Ashworth is President of the Helen Diller Family Comprehensive Cancer Center at the University of California, San Francisco. His work centers on cancer genetics and therapeutic discovery and development. He holds a BSc from Imperial College of Science and Technology and a PhD from University College London, and is a Fellow of the Royal Society.

Christine E. "Kricket" Seidman is the Thomas W. Smith Professor of Genetics and Medicine at Harvard Medical School and Brigham and Women's Hospital, with expertise in genetics and cardiovascular biology and medicine. She earned a BA from Harvard University and an MD from George Washington University School of Medicine, completing her residency at Johns Hopkins and a postdoctoral fellowship at Massachusetts General Hospital. She has been elected to the National Academy of Science and the National Academy of Medicine and co-founded MyoKardia.

Dan Littman is the Kimmel Professor of Molecular Immunology at NYU School of Medicine, with expertise in immunology and virology. He holds a BA from Princeton University and an MD and PhD from Washington University in St. Louis, and completed his residency and postdoctoral fellowship at Columbia University. He has co-founded biotechnology companies and received several awards in biomedical science.

David Sinclair is a Professor of Genetics at Harvard Medical School and Co-Director of the Paul F. Glenn Labs for the Biology of Aging, focusing on longevity and the biology of aging. He holds a BS and PhD from the University of New South Wales and completed a post-doctoral fellowship at MIT. He has co-founded numerous biotechnology companies and authored the New York Times bestseller "Lifespan."

Frances H. Arnold is the Linus Pauling Professor of Chemical Engineering, Bioengineering and Biochemistry at the California Institute of Technology, with expertise in protein engineering, synthetic biology, and biocatalysis. She holds a BS from Princeton University and a PhD from the University of California, Berkeley, where she also completed a postdoctoral fellowship. Her recognitions include the 2018 Nobel Prize in Chemistry and the National Medal of Technology and Innovation.

Freda Lewis-Hall previously served as Chief Medical Officer and Executive Vice President at Pfizer and at Vertex Pharmaceuticals, and as Senior Vice President at Bristol-Myers Squibb. She holds a BA from Johns Hopkins University and an MD from Howard University College of Medicine, and her expertise spans drug development and delivery, bio-pharmaceutical management, health disparities, and psychiatry.

Gordana Vunjak-Novakovic is a professor of biomedical engineering and medical sciences at Columbia University, where she leads the Laboratory for Stem Cells and Tissue Engineering. Her research centers on tissue engineering, organs-on-a-chip disease models, and regenerative medicine. She earned her BS, MS, and PhD from the University of Belgrade and is a member of the National Academies of Medicine, Engineering, and Inventors.

Gregg L. Semenza is the C. Michael Armstrong Professor of Genetic Medicine at Johns Hopkins School of Medicine and directs the Armstrong Oxygen Biology Research Center at Johns Hopkins Medicine. His research spans angiogenesis, cancer biology, oxygen biology, and transcriptional regulation. He earned a BA from Harvard College, an MD/PhD from the University of Pennsylvania, completed residency at Duke University Medical Center and a fellowship at Johns Hopkins, and received the 2019 Nobel Prize in Physiology or Medicine.

Jim J. Collins is the Termeer Professor of Medical Engineering & Science at MIT and an Institute Member of the Broad Institute of MIT and Harvard, with expertise in synthetic biology and systems biology. He holds a BA from the College of the Holy Cross and a PhD from the University of Oxford, where he was a Rhodes Scholar. His recognitions include the MacArthur Fellowship and membership in the National Academies of Medicine, Sciences, and Engineering.

Justin Hanes serves as Director of the Center of Nanomedicine at Johns Hopkins Medicine, with a research focus on nanomedicine. He holds a BS from the University of California Los Angeles and a PhD from the Massachusetts Institute of Technology. He was elected to the National Academy of Inventors in 2014 and named to MIT Technology Review's 35 Innovators Under 35 in 2003.

Michael A. Rogawski is a Distinguished Professor in the Department of Neurology at the University of California, Davis School of Medicine. His research focuses on neurological therapeutics, with particular expertise in neuropharmacology, antiepileptic drugs, epilepsy therapies, and headache treatments.

Sharma is a physician-scientist specializing in immunology, immunotherapy, and genitourinary medical oncology, and serves as Co-Director of the Parker Institute for Cancer Immunotherapy at The University of Texas MD Anderson Cancer Center. She earned a BA and MA from Boston University and an MD/PhD from Pennsylvania State University College of Medicine, completing a residency at New York Presbyterian Hospital, Weill Cornell Medical Center, and a postdoctoral fellowship at Memorial Sloan-Kettering Cancer Center. She has co-founded several biotechnology companies and served on numerous scientific advisory boards.

Paula T. Hammond is an Institute Professor of Chemical Engineering at the Massachusetts Institute of Technology and Dean of Engineering as of January 2026. Her research focuses on using electrostatic interactions and complementary mechanisms to develop functional materials with controlled architecture, particularly in nanomedicine applications including drug delivery, targeted nanoparticle therapeutics, and cancer treatment. Hammond has been elected to the National Academy of Sciences, the National Academy of Engineering, and the National Academy of Medicine, and has received numerous honors including the National Medal of Technology and Innovation, the Benjamin Franklin Medal for Chemistry, and the AIChE Charles M. A. Stine Award.

Philip D. Greenberg is a Professor of Oncology and Immunology at the University of Washington and an Investigator at the Parker Institute for Cancer Immunotherapy at Fred Hutchinson Cancer Research Center. His work spans immunology, immuno-oncology, cancer biology, genetic engineering, and cell therapy. He earned a BA from Washington University in St. Louis and an MD from the State University of New York, and completed his residency and postdoctoral fellowship at the University of California, San Diego.

Raju Kucherlapati is a Professor of Genetics at Harvard Medical School. He earned his PhD from the University of Illinois Urbana-Champaign and completed postdoctoral training at Yale University, following degrees earned in India. He was elected to the National Academy of Medicine and served on the Presidential Commission for the Study of Bioethical Issues from 2009 to 2017.

Samir Mitragotri is the Hiller Professor of Bioengineering at Harvard University, with research expertise in drug delivery and biomaterials. He earned a BS from the Institute of Chemical Technology in India and a PhD from the Massachusetts Institute of Technology, and has been elected to the National Academy of Engineering, the National Academy of Medicine, and the National Academy of Inventors. He has co-founded several life sciences companies.

Sangeeta N. Bhatia directs the Marble Center for Cancer Nanomedicine at MIT, with research focused on nanomedicine in liver disease and cancer. She holds a BSc from Brown University, an MD from Harvard Medical School, and a PhD from MIT. She has co-founded several biotechnology companies and received recognitions including the Lemelson-MIT Prize and election to the National Academies of Sciences, Medicine, and Engineering.

Titia de Lange directs the Anderson Center for Cancer Research at Rockefeller University, where she holds the Leon Hess Professorship in Cell Biology and Genetics. Her work spans cancer biology, chromosome biology, cell biology, and genetics. She earned her BA and PhD from the University of Amsterdam and completed postdoctoral training at the University of California, San Francisco.

Matthew Hobson is a Principal at Catalio Capital Management, where he focuses on therapeutics and diagnostics investments across the firm's venture and private credit strategies. He joined Catalio at its 2020 founding, having previously been a Postdoctoral Fellow at the Johns Hopkins School of Medicine, where he also earned a PhD in biophysics and biophysical chemistry. He holds a B.S. in chemistry and physics from Emory University.

Nicholas von Guionneau is a Principal at Catalio Capital Management, where he makes private credit and venture investments in healthcare companies, with a focus on medtech and neurotherapeutics. Before joining Catalio, he was a Postdoctoral Research Fellow at Johns Hopkins Medicine working on peripheral nerve regeneration and implantable neurodevices, drug delivery systems, and protein therapeutics, and earlier practiced as a clinician at Guy's and St. Thomas' NHS Trust in London. He holds an MBBS and a BSc in Medical Sciences from Imperial College School of Medicine.

Vicky Sostilio is Vice President of Marketing at Catalio Capital Management, covering North America and working with current and prospective investors across Catalio's strategies. She previously served as Head of Investor Relations and Marketing at HealthCor Management, a healthcare-focused long short equity fund, and spent six years at UBS as a Director on the Capital Introduction and Business Consulting team. She holds a B.S. in Finance with a minor in Computer Science from Wake Forest University.

Will Denehy is Vice President of Marketing at Catalio Capital Management UK, covering Europe, and works with current and prospective investors across Catalio's funds. He previously served as Investment Director at Odey Asset Management (2015-2022) and worked in wealth management sales at Fisher Investments (2013-2015). He holds a B.A. in History from the University of Bristol.